BR112023022530A2 - Inibidores de pcna e inibidores de egfr para tratamento de câncer - Google Patents
Inibidores de pcna e inibidores de egfr para tratamento de câncerInfo
- Publication number
- BR112023022530A2 BR112023022530A2 BR112023022530A BR112023022530A BR112023022530A2 BR 112023022530 A2 BR112023022530 A2 BR 112023022530A2 BR 112023022530 A BR112023022530 A BR 112023022530A BR 112023022530 A BR112023022530 A BR 112023022530A BR 112023022530 A2 BR112023022530 A2 BR 112023022530A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- pcna
- egfr
- cancer treatment
- inhibitor
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 108050006400 Cyclin Proteins 0.000 title abstract 2
- 102000009339 Proliferating Cell Nuclear Antigen Human genes 0.000 title abstract 2
- 229940121647 egfr inhibitor Drugs 0.000 title abstract 2
- 229940122532 PCNA inhibitor Drugs 0.000 abstract 2
- 101710168302 PCNA-inhibitor Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163182408P | 2021-04-30 | 2021-04-30 | |
| PCT/US2022/026928 WO2022232509A1 (en) | 2021-04-30 | 2022-04-29 | Pcna inhibitors and egfr inhibitors for cancer treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023022530A2 true BR112023022530A2 (pt) | 2024-01-16 |
Family
ID=83847341
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023022530A BR112023022530A2 (pt) | 2021-04-30 | 2022-04-29 | Inibidores de pcna e inibidores de egfr para tratamento de câncer |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240245634A1 (https=) |
| EP (1) | EP4330224A4 (https=) |
| JP (1) | JP2024516828A (https=) |
| KR (1) | KR20240004548A (https=) |
| CN (1) | CN117460714A (https=) |
| AU (1) | AU2022264802A1 (https=) |
| BR (1) | BR112023022530A2 (https=) |
| CA (1) | CA3217330A1 (https=) |
| IL (1) | IL307281A (https=) |
| MX (1) | MX2023012744A (https=) |
| WO (1) | WO2022232509A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025054318A1 (en) * | 2023-09-06 | 2025-03-13 | City Of Hope | Pcna inhibitors and uses thereof |
| CN120097860A (zh) * | 2023-12-05 | 2025-06-06 | 杜心赟 | 增殖细胞核抗原抑制剂、其制备方法、其中间体、其药物组合物和用途 |
| CN118546074B (zh) * | 2024-05-27 | 2025-06-06 | 安徽贝克制药股份有限公司 | 一种氘代增殖细胞核抗原抑制剂及其制备方法和其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108348512B (zh) * | 2015-09-17 | 2021-09-03 | 希望之城 | Pcna抑制剂 |
| JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
-
2022
- 2022-04-29 AU AU2022264802A patent/AU2022264802A1/en active Pending
- 2022-04-29 EP EP22796802.1A patent/EP4330224A4/en active Pending
- 2022-04-29 CN CN202280039160.XA patent/CN117460714A/zh active Pending
- 2022-04-29 US US18/288,692 patent/US20240245634A1/en active Pending
- 2022-04-29 IL IL307281A patent/IL307281A/en unknown
- 2022-04-29 CA CA3217330A patent/CA3217330A1/en active Pending
- 2022-04-29 JP JP2023566518A patent/JP2024516828A/ja active Pending
- 2022-04-29 BR BR112023022530A patent/BR112023022530A2/pt unknown
- 2022-04-29 KR KR1020237039721A patent/KR20240004548A/ko active Pending
- 2022-04-29 WO PCT/US2022/026928 patent/WO2022232509A1/en not_active Ceased
- 2022-04-29 MX MX2023012744A patent/MX2023012744A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3217330A1 (en) | 2022-11-03 |
| JP2024516828A (ja) | 2024-04-17 |
| CN117460714A (zh) | 2024-01-26 |
| AU2022264802A1 (en) | 2023-10-12 |
| EP4330224A4 (en) | 2025-03-19 |
| WO2022232509A1 (en) | 2022-11-03 |
| EP4330224A1 (en) | 2024-03-06 |
| MX2023012744A (es) | 2024-01-05 |
| IL307281A (en) | 2023-11-01 |
| US20240245634A1 (en) | 2024-07-25 |
| KR20240004548A (ko) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023022530A2 (pt) | Inibidores de pcna e inibidores de egfr para tratamento de câncer | |
| CL2022000922A1 (es) | Aminas bicíclicas como inhibidores de la cdk2. | |
| ECSP22098041A (es) | Inhibidores alostéricos de egfr y métodos de uso de estos | |
| BR112022017508A2 (pt) | Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos | |
| BR112022022634A2 (pt) | Inibidores de atr para o tratamento de câncer | |
| CR20190252A (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
| BR112023009531A2 (pt) | Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos | |
| CL2023003965A1 (es) | Inhibidores cdk2. | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| BR112022017724A2 (pt) | Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos | |
| CY1124613T1 (el) | Πυριμιδοπυριμιδινονες χρησιμες ως αναστολεις της wee-1 κινασης | |
| ECSP23019525A (es) | Anticuerpo anti-nectina-4, conjugado que lo incluye y aplicación de los mismos | |
| CL2008001743A1 (es) | Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende. | |
| MX2022004143A (es) | Compuesto que tiene actividad inhibidora de brd4, su método de preparación y su uso. | |
| BR112021025645A2 (pt) | Degradação de proteína alvo de parp14 para uso em terapia | |
| CL2022001794A1 (es) | Terapia combinada que comprende inhibidores de a2a/a2b y pd-1/pd-l1. | |
| BR112022012278A2 (pt) | Combinações | |
| BR112022012281A2 (pt) | Combinações | |
| BR112022012280A2 (pt) | Combinações | |
| ECSP22043592A (es) | Inhibidores de egfr alost?ricos y m?todos de uso de los mismos | |
| MX2022016496A (es) | Combinacion de un inhibidor del bromodominio cbp/p300 y un inhibidor del egfr para su uso en el tratamiento de la cpnm con mutacion del egfr. | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| CL2025000366A1 (es) | Composiciones y metodos para el tratamiento de presicion del cancer | |
| MX2021003263A (es) | Combinacion de un antagonista de proteina de muerte programada 1 (pd-1), un inhibidor de ataxia telangiectasia y proteina relacionada con rad3 (atr) y un agente de platino para el tratamiento de cancer. | |
| MX2022003001A (es) | Metodos para tratar el cancer mediante el uso de inhibidores del eje de pd-1 y anticuerpos anti-periostina. |